Follow us on:
Dedication / Services
To provide 50000 services and products to global scientific research units every year

SGN-CD19A(Denintuzumab mafodotin)

DESCRIPTION CATALOG # SIZE PRICE
Anti-Human CD19 Therapeutic Antibody TAB-891 1mg Please Inquiry
Product Detail
Cat
TAB-891
Product Overview
Recombinant humanized antibody expressed in CHO binding to human CD19. SGN-CD19A(Denintuzumab mafodotin) is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.
Target
CD19
Type
IgG1 - kappa
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in ELISA, FC, IP, FuncS, IF, Neut, ICC and most other immunological methods.
Predicted N terminal
QVQLQESG
Molecular Weight
Approximately 150 kDa
Purity
>95.0% as determined by analysis by RP-HPLC.
Size
1mg
Storage
At -20°C for one year.
Background
Introduction
SGN-CD19A(Denintuzumab mafodotin) is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.
Function
receptor signaling protein activity;
Gene ID
930
Synonyms
CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
Download Datasheet:

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

Online Inquiry
Please input "biolabs"(case insensitive) as verification code.
Loading...
Contact Us

USA
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email: 

Europe
Tel: 44-207-097-1828


© 2007 - 2017 Creative-Biolabs All Rights Reserved